A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

TRIAL DESIGN: Phase 3, randomized, controlled, multicenter, equivalence trial. METHODS: Recruitment of participants occurred between 04Februray2020 and 15July2020 at four centers in the Philippines: University of the East – Ramon Magsaysay Memorial Medical Center Inc., Quezon City; University of Phi...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlos, Josefina Cadorna, Tadesse, Birkneh Tilahun, Borja-Tabora, Charissa, Alberto, Edison, Ylade, Michelle C., Sil, Arijit, Kim, Deok Ryun, Ahn, Hyeon Seon, Yang, Jae Seung, Lee, Ji Yeon, Kim, Min Soo, Park, Jiwook, Kwon, Soo-Young, Kim, Hun, Yang, Seon-Young, Ryu, Ji-hwa, Park, Hokeun, Shin, Jong-hoon, Lee, Yoonyeong, Kim, Jerome H., Mojares, Zenaida Reynoso, Wartel, T. Anh, Sahastrabuddhe, Sushant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160840/
https://www.ncbi.nlm.nih.gov/pubmed/35664443
http://dx.doi.org/10.1016/j.lanwpc.2022.100484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160840/
https://www.ncbi.nlm.nih.gov/pubmed/35664443
http://dx.doi.org/10.1016/j.lanwpc.2022.100484

Ejemplares similares